Journal of Gynecologic Oncology

JGO遵循ICMJE关于使用人工智能的建议，使用此类技术的作者应在投稿信和稿件相应部分说明其使用情况，例如用于写作辅助的AI应在致谢部分报告。 模型中文摘要

The JGO follows the ICMJE recommendations regarding the use of AI (https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). According to the ICMJE recommendations on "Roles & Responsibilities," authors who utilized such technology should explain its use in both the cover letter and the appropriate section of the submitted work, if…

根据ICMJE，每位作者应充分参与工作并对内容承担公开责任，不符合作者资格标准的其他贡献者应在致谢部分注明。 模型中文摘要

In accordance with the ICMJE, each author should have participated sufficiently in the work to take public responsibility for the content (http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). All other contributors who do not meet sufficient criteria for authorship should be noted in the Acknowledgments section. Otherwise, any …

JGO的所有贡献者必须披露与对稿件主题有投资、许可或其他商业利益的实体之间的财务及其他关系，通讯作者应在投稿过程中代表所有作者回答相关问题。 模型中文摘要

All contributors to JGO are required to disclose financial and other relationships with entities that have investment, licensing, or other commercial interests in the subject matter under consideration in their article. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other commercial entities whose pr…

JGO接受ICMJE关于数据共享声明的建议，自2019年2月1日起，所有报告临床试验结果的稿件应按照ICMJE指南提交数据共享声明。 模型中文摘要

JGO accepts the ICMJE Recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines from 1 Feb 2019.

所有发表论文成为亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会的永久财产，文章发表后代表作者应上传版权转让表，如引用其他版权作品须获得版权所有者的书面许可并在文中注明来源。 模型中文摘要

All published papers become the permanent property of the Asian Society of Gynecologic Oncology, the Korean Society of Gynecologic Oncology, and the Japan Society of Gynecologic Oncology. Upon publication of an article, a representative author should upload a Copyright Transfer Form. Please download Copyright Transfer Form.pdf in the journal homepage (https://ejgo.org/index.php?body=instructions).…

JGO是开放获取期刊，文章根据知识共享署名许可条款发布，允许在注明原文出处的情况下进行不受限制的非商业使用、分发和复制。 模型中文摘要

JGO is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Permission must be requested from the Editorial Office of JGO to use tables or figures appearing in the journal in other periodicals, books, or …

编辑通过作者推荐的审稿人、编委会成员推荐或编委会专家数据库选择同行评审专家，审稿人的决定分为接受、小修、大修和拒稿。 模型中文摘要

The Editor selects peer reviewers by using reviewer suggested by authors, by recommendation of the Editorial Board members or from the specialist database owned by the Editorial Board. Acceptance of the manuscript is decided, based on the critiques and recommended decision of the reviewers. A reviewer's decision is made as “Accept,” “Minor revisions,” “Major revisions”, and “Reject”. If there is m…

JGO考虑发表曾在公认的非营利预印本平台（如medRxiv、arXiv、bioRxiv）发布过的稿件，作者必须保留此类发布的版权，预印本信息须在投稿时披露，且不支持将回应编辑意见和同行评审的修改稿或最终发表版本发布到预印本服务器。 模型中文摘要

JGO will consider publication of manuscripts that contain information previously posted on any recognized, not-for-profit, preprint platform, such as medRxiv, arXiv, bioRxiv. Authors must retain copyright to such postings. Preprint information must be disclosed at submission so reviewers and editors can evaluate the preprinted information and compare it with the submitted manuscript. Please note t…

JGO全文自2008年第19卷起已在PubMed Central存档。 模型中文摘要

The full text of JGO has been archived in PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/883/) from the volume 19, 2008.

JGO has incorporated specific guidelines for reporting randomized controlled trials (i.e., CONSORT), meta-analyses and systematic reviews of randomized controlled trials (i.e., PRISMA), meta-analyses and systematic reviews of observational studies (i.e., MOOSE), observational studies (i.e., STROBE), studies of diagnostic accuracy (i.e., STARD), tumor marker prognostic studies (i.e., REMARK), quali…